These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12429911)

  • 21. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
    Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
    J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 expression in CMV-infected cells: association with the alternative expression of the p53 transactivated genes p21/WAF1 and MDM2.
    García JF; Piris MA; Lloret E; Orradre JL; Murillo PG; Martínez JC
    Histopathology; 1997 Feb; 30(2):120-5. PubMed ID: 9067734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel p53 mutant retained functional activity in lung carcinomas.
    Ko JL; Chiao MC; Chang SL; Lin P; Lin JC; Sheu GT; Lee H
    DNA Repair (Amst); 2002 Sep; 1(9):755-62. PubMed ID: 12509279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accumulation of soluble and nucleolar-associated p53 proteins following cellular stress.
    Klibanov SA; O'Hagan HM; Ljungman M
    J Cell Sci; 2001 May; 114(Pt 10):1867-73. PubMed ID: 11329373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53.
    Kitazono M; Bates S; Fok P; Fojo T; Blagosklonny MV
    Cancer Biol Ther; 2002; 1(6):665-8. PubMed ID: 12642691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
    Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
    Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
    Ramondetta L; Mills GB; Burke TW; Wolf JK
    Clin Cancer Res; 2000 Jan; 6(1):278-84. PubMed ID: 10656459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1.
    Zacharatos PV; Gorgoulis VG; Kotsinas A; Manolis EN; Liloglou T; Rassidakis AN; Kanavaros P; Field JD; Halazonetis T; Kittas C
    Anticancer Res; 1999; 19(1A):579-87. PubMed ID: 10226602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53, p21(WAF1/CIP1), and MDM2 involvement in proliferation and apoptosis in an in vitro model of conditionally immortalized human vascular smooth muscle cells.
    Hsieh JK; Kletsas D; Clunn G; Hughes AD; Schachter M; Demoliou-Mason C
    Arterioscler Thromb Vasc Biol; 2000 Mar; 20(3):636-44. PubMed ID: 10712385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of p21/waf1 in oral squamous cell carcinomas--correlation with p53 and mdm2 and cellular proliferation index.
    Ng IO; Lam KY; Ng M; Regezi JA
    Oral Oncol; 1999 Jan; 35(1):63-9. PubMed ID: 10211312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation.
    An WG; Chuman Y; Fojo T; Blagosklonny MV
    Exp Cell Res; 1998 Oct; 244(1):54-60. PubMed ID: 9770348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer.
    Salnikow K; Costa M; Figg WD; Blagosklonny MV
    Cancer Res; 2000 Oct; 60(20):5630-4. PubMed ID: 11059752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The permissive effect of p21(Waf1/Cip1) on DNA synthesis is dependent on cell type: effect is absent in p53-inactive cells.
    Weiss RH; Randour CJ
    Cell Signal; 2000 Jun; 12(6):413-8. PubMed ID: 10889470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human T-cell leukemia virus type 1 Tax activates cyclin-dependent kinase inhibitor p21/Waf1/Cip1 expression through a p53-independent mechanism: Inhibition of cdk2.
    Chowdhury IH; Farhadi A; Wang XF; Robb ML; Birx DL; Kim JH
    Int J Cancer; 2003 Nov; 107(4):603-11. PubMed ID: 14520699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human melanoma cell line UV responses show independency of p53 function.
    Haapajärvi T; Pitkänen K; Laiho M
    Cell Growth Differ; 1999 Mar; 10(3):163-71. PubMed ID: 10099830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3.
    Sharma K; Patel YC; Srikant CB
    Mol Endocrinol; 1996 Dec; 10(12):1688-96. PubMed ID: 8961277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity.
    Giannakakou P; Robey R; Fojo T; Blagosklonny MV
    Oncogene; 2001 Jun; 20(29):3806-13. PubMed ID: 11439344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines.
    Bae I; Smith ML; Sheikh MS; Zhan Q; Scudiero DA; Friend SH; O'Connor PM; Fornace AJ
    Cancer Res; 1996 Feb; 56(4):840-7. PubMed ID: 8631022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited role of N-terminal phosphoserine residues in the activation of transcription by p53.
    Jackson MW; Agarwal MK; Agarwal ML; Agarwal A; Stanhope-Baker P; Williams BR; Stark GR
    Oncogene; 2004 May; 23(25):4477-87. PubMed ID: 15064747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.
    Kaku S; Iwahashi Y; Kuraishi A; Albor A; Yamagishi T; Nakaike S; Kulesz-Martin M
    Nucleic Acids Res; 2001 May; 29(9):1989-93. PubMed ID: 11328884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.